Search the site

COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years o

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group

CP Movetime: A wearable sensor and user interface to reduce sedentary behaviours in non-ambulant children and youth with cerebral palsy

CP Movetime aims to establish and test a technology-based application to improve health outcomes by monitoring device measured sedentary behaviours in non-ambulant children and youth with cerebral palsy.

DEFEND CF: Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis.

Defining the cellular immune response to vaccines for enhanced protection from invasive pneumococcal disease

Peter Lea-Ann Ruth Richmond Kirkham Thornton MBBS MRCP(UK) FRACP PhD PhD Head, Vaccine Trials Group Co-Head, Bacterial Respiratory Infectious Disease

Determinants of incomplete vaccination and non-vaccination among WA children

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Determinants of prenatal alcohol exposure among Aboriginal women in the Pilbara: Developing a statistically validated model of prenatal alcohol consumption for evidence based intervention development

Investigators: Dave Tucker (PhD candidate), Associate Professor Roz Walker, Dr Martyn Symonds, Dr Nyanda McBride The overarching aim of the proposed

Developing a ‘Food Atlas’ for Western Australia to map, measure and monitor food access

This unique interdisciplinary project, funded by Healthway, aims to develop a Food Atlas tool for mapping, measuring, and monitoring food access across Western Australia.

Developing a human challenge model of GAS infection

NHMRC funding has been awarded for 4 years to Murdoch Childrens Research Institute for this project, with collaboration from Professor Jonathan Carapetis at The Kids.

Developing a novel therapeutic pipeline for antibiotic resistant bacterial lung infection in children: investigating and assessing the potential phage therapy

Antimicrobial resistance is a global health crisis, which has accelerated due to the overuse of antibiotics.

Developing and characterising juvenile models of aggressive paediatric brain cancers for the evaluation of novel immunotherapies.

While profound treatment responses have been realised using immunotherapy for some cancer types, this is yet to be seen for paediatric brain cancer patients.